Idelalisib is active in patients with Chemotherapy and Rituximab-Refractory Indolent Non-Hodgkin Lymphoma

Peter Martin, MD
Peter Martin, MD

On January 22nd, the New England Journal of Medicine published the results of an international phase II clinical trial co-authored by Dr. Peter Martin. The trial was designed to evaluate the efficacy of the oral drug idelalisib in patients with indolent non-Hodgkin lymphoma resistant to chemotherapy and rituximab. The results were remarkable in this challenging-to-treat population. Highlights from the publication include the following:

  • Idelalisib was well tolerated.
  • The majority of patients responded and the average time to response was 1.9 months.
  • Continued use of idelalisib saw sustained responses beyond 1 year, exceeding responses of prior therapy.

 

Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s